


2/ 19 Figure 2






Figure 3A





Figure 3B

4/ 19 Figure 4 Incorporation of BrdU Anti-PTHrP antibodies C-term Région int. lg G 5 120 8 09 40 20 100 Incorporation of BrdU (% of control) Anti-PTHrP antibodies C-term Number of cells Region int IgG ᅙ 8 9 4 2

Cell density (% of control)

• • • • •

5/ 19 **Figure 5**



Anti-PTHrP antibodies

Anti-PTHrP antibodies

2

9

Cell density (% of control)


80


40


20


6/ 19 Figure 6 Incorporation of BrdU Région int. N-term ᇙ 20 80 9 40 Incorporation of BrdU (% of control) C-term Région int. Number of cells N-term

7/ 19 **Figure 7**










10/ 19

Figure 10 Treatment by antagonist

Control Treatment



11/ 19






Figure 11A





12/ 19




13/ 19

Figure 13









16/ 19

Figure 16




17/ 19 **Figure 17**



18/ 19

Figure 18



19/ 19

Figure 19

